NCT02658838

The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Beijing Anzhen Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.

Detailed description

Ticagrelor is a new drug compared with clopidogrel. It has a stronger antiplatelet capacity. After PCI，whether using low molecular weight heparin can make patients better prognosis or not, What's more，full amount or half amount low molecular weight heparin?, also investigators want to explore that whether it may lead to more bleeding events.

Conditions

• LOVASTATIN/TICAGRELOR [VA Drug Interaction]

Interventions

Type	Name	Description
DRUG	Ticagrelor	Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
DRUG	full amount low molecular weight heparin	Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
DRUG	half amount low molecular weight heparin	Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
DRUG	No low molecular weight heparin	Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

Timeline

• Start date: 2015-04-01
• Primary completion: 2016-08-01
• Completion: 2017-09-01
• First posted: 2016-01-20
• Last updated: 2016-01-20

Locations

1 site across 1 country: China